Bevacizumab in high-grade gliomas: past, present, and future.

摘要: The survival of patients with high-grade gliomas (anaplastic and glioblastoma) remains poor despite current treatment modalities. However, an enhanced understanding gliomagenesis is supporting the development targeted molecular therapies potential for improving clinical outcomes. Glioblastoma (GBM) characterized by extensive microvascular proliferation production large amounts VEGF. Bevacizumab a humanized IgG1 monoclonal antibody that selectively binds high affinity to human VEGF neutralizes VEGF’s biologic activity. Preclinical data indicate angiogenesis essential GBM cells. A number studies have evaluated outcomes both newly diagnosed recurrent bevacizumab in prospective manner. Here, we discuss role anaplastic upfront setting.